Brainstorm Cell Therapeutics Stock Forum

$Brainstorm Cell Therapeutics(BCLI.US)$
⚫️BCLI's primary target is the fatal amyotrophic lateral sclerosis (ALS/MND/Lou Gehrig's).
▪️Post hoc analysis of BCLI's PIII trial data shows BCLI's NurOwn® (debamestrocel, MSC-NTF), has STATISTICALLY SIGNIFICANT clinical effects on early-stage ALS sufferers and that placebo trialists deteriorate faster.
▪️Peer reviewed research (Mar 2024) indicated that BCLI's NurOwn® has a positive impact on NfL biomarkers...

$Brainstorm Cell Therapeutics(BCLI.US)$ Bet you won't do it again. 😉

$Brainstorm Cell Therapeutics(BCLI.US)$ damn....skinny drop....one more push

$Brainstorm Cell Therapeutics(BCLI.US)$PIII post hoc analysis revealed the clinical effectiveness of its NurOwn stem cell Motor Neuron Disease therapy. PIIIb has FDA approval + success can create a 10x catalyst effect.

$Brainstorm Cell Therapeutics(BCLI.US)$BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation
Looks promising here.

$Brainstorm Cell Therapeutics(BCLI.US)$ On June 3, 2024, the Company received notice from Nasdaq that, based upon the completed questionnaire and the expedited review process, the Nasdaq Hearing Panel had granted the Company a temporary exception until October 21, 2024 to, if necessary, effect the reverse stock split and thereafter regain compliance with the Minimum Bid Price Requirement. The Nasdaq Hearing Panel noted that the temporary exception was granted base...

$Brainstorm Cell Therapeutics(BCLI.US)$ 👁

$Brainstorm Cell Therapeutics(BCLI.US)$ Ya'll ready for this...🔊🎶🎶

$Brainstorm Cell Therapeutics(BCLI.US)$
one could possibly read this as 1.5 million shares being shorted today. Wonder how many will lose their shorts on this one. Projected price of 2.55. Maybe I should load more.